Welcome!

Release Management Authors: Pat Romanski, Elizabeth White, David H Deans, Liz McMillan, Jnan Dash

News Feed Item

Eisai and UCL Form Major Drug Discovery Alliance to Develop New Therapeutics for Neurological Diseases

HATFIELD, England, December 13, 2012 /PRNewswire/ --

UCL and the Japanese pharmaceutical company Eisai, today announce the agreement to establish a major drug discovery and development collaboration. The unique alliance will involve researchers from both organisations working together to investigate innovative new ways of treating neurological diseases such as Alzheimer's, Parkinson's and other related disorders. The goal of the collaboration will be to identify and validate novel drug targets, develop new therapeutics and evaluate them in proof-of-concept clinical trials.  

This will be the first time that joint research is conducted by a partnership involving a public institution in the UK and a pharmaceutical company. UCL and Eisai will form a Therapeutic Innovation Group (TIG) which will comprise experienced scientists from both UCL and Eisai with the principal function of facilitating and coordinating the discovery and assessment of emerging therapeutic targets involved in neurological diseases. The TIG will also be responsible for the co-development of completely new research areas of interest. A Joint Steering Committee (JSC) will be established to govern the TIG and will be co-chaired by UCL's Professor Alan Thompson and Eisai's Neuroscience Unit President, Dr Lynn Kramer.

UCL carries out world-class research into the genetic and mechanistic causes of neurodegenerative diseases. It also has a wealth of expertise in clinical translation and this collaboration is expected to involve scientists and clinicians at UCL's new Leonard Wolfson Experimental Neurology Centre located in Queen Square, London. An alliance with UCL also forms a major part of Eisai's Open Innovation initiative to explore external ideas and paths to drug discovery through partnership. Eisai will provide drug discovery and development resource and know-how, assay development capabilities and medicinal chemistry expertise. In addition, Eisai has extensive experience in regulatory and clinical expertise through successful drug launches of neurological medicines. UCL will also receive milestones payments as projects progress, and, in addition, royalties on therapies successfully brought to market.

The on-going partnership with UCL is only one example of the company's continued commitment to the UK life sciences industry. This year, Eisai announced the transfer of global manufacturing for its new epilepsy medicine, Fycompa® (perampanel) to the UK. The first-in-class treatment was first launched in the UK in 2012 and is currently being sequentially launched throughout Europe. Today's announcement further consolidates the UK's position as a major centre of Eisai's commercial and growth strategy, and its continuing commitment to neuroscience research. Eisai already has one of the largest dementia research units in the UK and around 200 of the company's 500 UK employees are currently employed in R&D related positions across multiple therapeutic areas at Eisai's £100 million EMEA headquarters in Hatfield, UK.

Dr Lynn Kramer, President, Eisai Neuroscience Product Creation Unit, said: "Neurodegenerative diseases such as Alzheimer's and Parkinson's disease represent a significant unmet medical need due to lack of effective treatments that can prevent disease progression. UCL's is a world-class academic institution with specialised research capabilities and we expect this exciting partnership to be very successful. In this unique collaboration, we hope our complementary expertise will identify potential new drug targets that we can bring to market and make available to patients that need it the most.

Professor Sir John Tooke, Vice Provost for Health at UCL, said; "This is a genuinely new way of collaborating on pharmaceutical research for UCL, with exciting implications for research with the potential to lead to step changes in the treatment of diseases which affect the nervous system, such as Alzheimer's. It will already build on many years of close working and collaboration with Eisai, which I am confident will lead to the development of much-needed, new effective therapeutic agents."

Commenting on the partnership, Professor Stephen Caddick, Vice-Provost (Enterprise) at UCL, added:

"UCL is committed to working with partners who have a shared vision to translate research findings into products which will have a tangible, positive impact on society. This strategic alliance between UCL and Eisai combines research excellence, clinical insight and commercial expertise which will undoubtedly improve prospects for development of new treatments for patient benefits."

Notes to Editors

Eisai have a long and established history of scientific investment and partnership in the UK:

  • Eisai's first investments into UK R&D began 20 years ago with a landmark partnership with the neurosciences department at UCL, established to undertake world-leading scientific research into neurodegenerative diseases.
  • After entering a new phase in 2011, the company's Neuroscience Product Creation Unit (Neuroscience PCU) and UCL are currently engaging in joint research into neurodegenerative diseases, including biomarker research and drug discovery.
  • Eisai is committed to making further contributions to address key unmet medical needs in neurosciences by maintaining and strengthening the relationship built up with UCL, whilst at the same time leveraging the knowledge accumulated over the course of the partnership for the benefit of patients and their families in Europe and beyond.

About Eisai

Eisai recently expanded their UK Hatfield commercial, research and manufacturing facility which now supports the company's growing EMEA business.

Eisai concentrates its R&D activities in three key areas:

  • Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight loss
  • Oncology including: anticancer therapies; tumour regression, tumour suppression, antibodies, etc.
  • Vascular/Immunological reaction including: thrombocytopenia, rheumatoid arthritis, psoriasis, inflammatory bowel disease

With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 11,000 people worldwide. In Europe, Eisai undertakes sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech Republic, Slovakia, the Netherlands, Belgium, Luxembourg, the Middle East and Russia.

For further information please visit our web site http://www.eisai.com.

About UCL

Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. In the 2008 Research Assessment Exercise (RAE), UCL was rated the leading research university in London, and third in the UK overall, for the volume of research judged to be 'of world-leading quality'.

According to the Thomson Scientific Citation Index, which catalogues journal articles and citations in the sciences, social sciences, and arts and humanities, UCL is the second most highly cited European university and 15th in the world. UCL enjoys the lowest overall student to academic ratio of any public UK university. UCL is among the world's top universities, as reflected by performance in a range of international rankings and tables. UCL currently has 25,000 students from 150 countries, and over 9,000 employees. UCL's annual income is over £800 million.

For more information about UCL visit http://ucl.ac.uk/about-ucl 

Follow us on Twitter @uclnews

Date of preparation: December 2012

Job code: Corporate-UK2010

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
No hype cycles or predictions of a gazillion things here. IoT is here. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, an Associate Partner of Analytics, IoT & Cybersecurity at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He also discussed the evaluation of communication standards and IoT messaging protocols, data...
The 22nd International Cloud Expo | 1st DXWorld Expo has announced that its Call for Papers is open. Cloud Expo | DXWorld Expo, to be held June 5-7, 2018, at the Javits Center in New York, NY, brings together Cloud Computing, Digital Transformation, Big Data, Internet of Things, DevOps, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
Nordstrom is transforming the way that they do business and the cloud is the key to enabling speed and hyper personalized customer experiences. In his session at 21st Cloud Expo, Ken Schow, VP of Engineering at Nordstrom, discussed some of the key learnings and common pitfalls of large enterprises moving to the cloud. This includes strategies around choosing a cloud provider(s), architecture, and lessons learned. In addition, he covered some of the best practices for structured team migration an...
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, examined the regulations and provided insight on how it affects technology, challenges the established rules and will usher in new levels of diligence arou...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, provided a fun and simple way to introduce Machine Leaning to anyone and everyone. He solved a machine learning problem and demonstrated an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intelligence and B...
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, discussed how they built...
22nd International Cloud Expo, taking place June 5-7, 2018, at the Javits Center in New York City, NY, and co-located with the 1st DXWorld Expo will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud ...
22nd International Cloud Expo, taking place June 5-7, 2018, at the Javits Center in New York City, NY, and co-located with the 1st DXWorld Expo will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud ...
DevOps at Cloud Expo – being held June 5-7, 2018, at the Javits Center in New York, NY – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Among the proven benefits,...
@DevOpsSummit at Cloud Expo, taking place June 5-7, 2018, at the Javits Center in New York City, NY, is co-located with 22nd Cloud Expo | 1st DXWorld Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait...
Cloud Expo | DXWorld Expo have announced the conference tracks for Cloud Expo 2018. Cloud Expo will be held June 5-7, 2018, at the Javits Center in New York City, and November 6-8, 2018, at the Santa Clara Convention Center, Santa Clara, CA. Digital Transformation (DX) is a major focus with the introduction of DX Expo within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive ov...
SYS-CON Events announced today that T-Mobile exhibited at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on qua...
SYS-CON Events announced today that Cedexis will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Cedexis is the leader in data-driven enterprise global traffic management. Whether optimizing traffic through datacenters, clouds, CDNs, or any combination, Cedexis solutions drive quality and cost-effectiveness. For more information, please visit https://www.cedexis.com.
SYS-CON Events announced today that Google Cloud has been named “Keynote Sponsor” of SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Companies come to Google Cloud to transform their businesses. Google Cloud’s comprehensive portfolio – from infrastructure to apps to devices – helps enterprises innovate faster, scale smarter, stay secure, and do more with data than ever before.
SYS-CON Events announced today that Vivint to exhibit at SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California. As a leading smart home technology provider, Vivint offers home security, energy management, home automation, local cloud storage, and high-speed Internet solutions to more than one million customers throughout the United States and Canada. The end result is a smart home solution that sav...
SYS-CON Events announced today that Opsani will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Opsani is the leading provider of deployment automation systems for running and scaling traditional enterprise applications on container infrastructure.
SYS-CON Events announced today that Nirmata will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Nirmata provides a comprehensive platform, for deploying, operating, and optimizing containerized applications across clouds, powered by Kubernetes. Nirmata empowers enterprise DevOps teams by fully automating the complex operations and management of application containers and its underlying ...
SYS-CON Events announced today that Opsani to exhibit at SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California. Opsani is creating the next generation of automated continuous deployment tools designed specifically for containers. How is continuous deployment different from continuous integration and continuous delivery? CI/CD tools provide build and test. Continuous Deployment is the means by which...